Clinical trials: Macular Telangiectasia
Macular Telangiectasia Type 2 (MacTel)
Study of Serine Supplementation to Protect Vision in MacTel
The goal of this clinical trial is to look at the efficacy and safety of giving oral serine (an amino acid) on the progression of structural and functional changes of the retina in people with MacTel type 2.
- Trial name
- SEErine (NCT07342439)
- Testing
- L-serine
- Where
- 12 sites in United States, Australia and 3 more
- Volunteers
- 120 people
- Sponsor
- The Lowy Medical Research Institute Limited
Macular Telangiectasia
Ranibizumab Injections to Treat Macular Telangiectasia Without New Blood Vessel Growth
This study will examine whether the drug ranibizumab (Lucentis) can help prevent vision loss in people with macular telangiectasia, a condition in which new blood vessels grow in the retina at the back of the eye and can leak.
- Trial name
- NCT00685854
- Testing
- Ranibizumab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Eye Institute (NEI)
Macular Telangiectasia Type 2
A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol B
This study is a phase 3, randomized, multi-center study to evaluate the efficacy and safety of the NT-501 implants in participants with macular telangiectasia type 2.
- Trial name
- NCT03319849
- Testing
- NT-501
- Where
- 27 sites in United States, Australia and 1 more
- Volunteers
- 119 people
- Sponsor
- Neurotech Pharmaceuticals
Retinal Diseases, Telangiectasis
High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia
Idiopathic Parafoveal Telangiectasia (IPT) [also known as Idiopathic Perifoveal Telangiectasia, Idiopathic Juxtafoveal Telangiectasia (IJT, JFT) and Macular Telangiectasia (MacTel)] is a disorder of unknown etiology.
- Trial name
- HD-LIPT (NCT01205035)
- Testing
- ranibizumab 2.0mg
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Eye Center of Northern Colorado, P.C.
Macular Telangiectasia Type 2 (MacTel)
A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol A
This study is a phase 3, randomized, multi-center study to evaluate the efficacy and safety of the NT-501 implants in participants with macular telangiectasia type 2.
- Trial name
- NCT03316300
- Testing
- NT-501
- Where
- 20 sites in United States, Australia and 2 more
- Volunteers
- 120 people
- Sponsor
- Neurotech Pharmaceuticals
Telangiectasia
Injected Ranibizumab to Treat Macular Telangiectasia Without New Blood Vessel Formation
This study will examine whether the drug ranibizumab is an effective treatment for macular telangiectasia, a condition in which existing blood vessels near the macula (the back part of the eye responsible for sharp central…
- Trial name
- NCT00457145
- Testing
- Ranibizumab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Eye Institute (NEI)
Diabetic Macular Edema, Branch Retinal Vein Occlusion
Non-damaging Retinal Laser Therapy With PASCAL Laser for Macular Diseases
This trial seeks to prove the safety and efficacy of photothermal stimulation treatment to diabetic macular edema, chronic central serous retinopathy, macular edema secondary to branch retinal vein occlusion and macular…
- Conditions
- Diabetic Macular Edema, Branch Retinal Vein Occlusion, Chronic Central Serous Retinopathy, Macular Telangiectasia
- Trial name
- EPM (NCT01975103)
- Testing
- Topcon Endpoint Management
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- Federal University of Rio Grande do Sul
Retinal Telangiectasis, Idiopathic Juxtafoveal Retinal Telangiectasia
A Study to Evaluate THR-317 Treatment for Macular Telangiectasia Type 1 (MacTel 1)
This study is conducted to evaluate the safety of THR-317 when administered intravitreally and to assess the compound's efficacy in reducing central subfield thickness (CST) and improving best-corrected visual acuity (BCVA) in…
- Trial name
- NCT03669393
- Testing
- THR-317 8mg
- Where
- 3 sites in France, Switzerland
- Volunteers
- 8 people
- Sponsor
- ThromboGenics
Macular Telangiectasia Type 2
Serine and Fenofibrate Study in Patients With MacTel Type 2
This is a Phase 2a study of the effect of serine supplementation and fenofibrate treatment on serum deoxysphingolipid levels in patients with macular telangiectasia type 2 (MacTel). This study involves six arms.
- Trial name
- SAFE (NCT04907084)
- Testing
- Serine, Fenofibrate
- Where
- 9 sites in United States, United Kingdom
- Volunteers
- 89 people
- Sponsor
- The Lowy Medical Research Institute Limited
Telangiectasia
Injected Ranibizumab to Treat Macular Telangiectasia With New Blood Vessel Formation
This study will examine whether the drug ranibizumab is an effective treatment for macular telangiectasia, a condition in which existing blood vessels near the macula (the back part of the eye responsible for sharp central…
- Trial name
- NCT00457067
- Testing
- Ranibizumab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Eye Institute (NEI)
Telangiectasia
Ranibizumab in Idiopathic Parafoveal Telangiectasia (RIPT) Trial
This research is being done to look at the effects of an experimental drug, ranibizumab, for the treatment of a condition called "idiopathic parafoveal telangiectasia" or IPT.
- Trial name
- NCT00378196
- Testing
- Ranibizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Johns Hopkins University
Type 2 Idiopathic Macular Telangiectasia
Ranibizumab to Treat Type 2 Idiopathic Macular Telangiectasia (RAMA-Trial)
The purpose of this study is to investigate if a new drug called ranibizumab is effective to treat a rare bilateral disease of the macula: type 2 idiopathic macular telangiectasia (type 2 IMT).
- Trial name
- NCT00504400
- Testing
- Intravitreal injection ranibizumab
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- University Hospital, Bonn
Macular Telangiectasia
MacTel Laser Study
This is a two armed Single Masked Pilot Study enrolling participants with Macular Telangiectasia Type 2 who will be randomized to undergo either a subthreshold photothermal treatment or a sham procedure to one eye.
- Trial name
- NCT03321916
- Testing
- 577-nm PASCAL laser
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- The Lowy Medical Research Institute Limited
MacTel (Macular Telangiectasia) Type 2
Extension Study of NT-501 Ciliary Neurotrophic Factor (CNTF) Implant for Macular Telangiectasia (MacTel)
This was a prospective, multicenter, single-masked, sham-controlled extension study designed to provide long-term safety and efficacy follow-up data for subjects with MacTel who had NT-501 implanted intraocularly and/or underwent…
- Trial name
- NCT03071965
- Testing
- Ciliary neurotrophic factor (CNTF), Surgery
- Where
- 11 sites in United States, Australia
- Volunteers
- 70 people
- Sponsor
- Neurotech Pharmaceuticals
Macular Telangiectasia Type 2
A Study to Determine the Safety and Efficacy of NT-501 With MHFM
This study is to determine the long-term levels of CNTF, and the clinical safety and efficacy of the NT-501 implants with the Medica Hollow Fiber Membrane (MHFM) in participants with macular telangiectasia type 2.
- Trial name
- NCT06397131
- Testing
- NT-501 CNTF Implant
- Where
- 6 sites in United States, Australia
- Volunteers
- 12 people
- Sponsor
- Neurotech Pharmaceuticals
Coats' Disease, Idiopathic Retinal Telangiectasia
Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy
The purpose of this study is to evaluate the safety and tolerability of intravitreal injections of ranibizumab in the treatment of AMD variants and other choroidal neovascularization (CNV) related conditions (Coats' disease…
- Conditions
- Coats' Disease, Idiopathic Retinal Telangiectasia, Retinal Angiomatous Proliferation, Polypoidal Choroidal Vasculopathy
- Trial name
- FVF4140S (NCT00470977)
- Testing
- ranibizumab injection (0.5 mg)
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Manhattan Eye, Ear & Throat Hospital
Macular Telangiectasia Type 2 (MacTel)
Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants
The purpose of this global, multicenter, open-label, Phase 4 clinical extension study is to evaluate the long-term safety and efficacy of revakinagene taroretcel-lwey (Encelto™; hereinafter referred to as NT-501), in participants…
- Trial name
- NCT06971939
- Testing
- NT-501/revakinagene taroretcel-lwey
- Where
- 26 sites in United States, Australia
- Volunteers
- 234 people
- Sponsor
- Neurotech Pharmaceuticals
Macular Telangiectasia
Comparative Multicenter Randomized Study of Aflibercept Versus Placebo in Macular Telangiectasia Type 1
Idiopathic juxtafoveal telangiectasia type 1 is a rare unilateral disease that mostly affects men before 50 years of age. Mac Tel 1 are characterized by microvascular telangiectasia and increased tortuosity of the macular…
- Trial name
- TELeMAC (NCT03845049)
- Testing
- Inclusion examinations, Aflibercept Injection [Eylea], Examinations during study (every month)
- Where
- France
- Volunteers
- 16 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Macular Telangiectasia Type 2
Safety Study to Evaluate Bilateral CNTF Implants in Subjects With MacTel Type 2
This is a multi-center, open-label, 6-month study to evaluate the safety of bilateral CNTF implants in participants with Macular Telangiectasia Type 2.
- Trial name
- NCT04729972
- Testing
- NT-501 CNTF implant
- Where
- 10 sites in United States, Australia
- Volunteers
- 33 people
- Sponsor
- Neurotech Pharmaceuticals
Idiopathic Juxtafoveal Telangiectasia
Ciliary Neurotrophic Factor (CNTF) Safety Trial in Patients With Macular Telangiectasia (Mactel)
This study is a phase 1, open label, non-randomized, multi-center, pilot study to evaluate the safety and tolerability of NT-501 implants in 5-7 study participants with Mactel.
- Trial name
- NCT01327911
- Testing
- NT-501 implant
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Neurotech Pharmaceuticals